Prescott Group Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Prescott Group Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Sell	616 -253	-29%	-$112K	0.03%	273
2026 Q1	$388K	Hold	869	–	–	0.04%	245
2025 Q4	$394K	Hold	869	–	–	0.04%	263
2025 Q3	$340K	Hold	869	–	–	0.04%	231
2025 Q2	$387K	Buy	869 +272	+46%	+$125K	0.05%	231
2025 Q1	$289K	Buy	+597	New	+$278K	0.04%	210
2018 Q4	–	Sell	-5,000	Closed	-$964K	–	259
2018 Q3	$964K	Hold	5,000	–	–	0.19%	120
2018 Q2	$850K	Hold	5,000	–	–	0.16%	136
2018 Q1	$815K	Hold	5,000	–	–	0.18%	131
2017 Q4	$749K	Hold	5,000	–	–	0.16%	119
2017 Q3	$760K	Buy	+5,000	New	+$753K	0.15%	120

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Prescott Group Capital Management's VRTX Position: Q2 2026 in Review

Prescott Group Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 29% in Q2 2026, selling an estimated $112K and leaving 616 shares worth $306K. The position accounts for 0.03% of the portfolio, ranked #273.

Prescott Group Capital Management first reported a position in VRTX in Q3 2017 and has held it in 11 quarters since. The position peaked at $964K in Q3 2018. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Prescott Group Capital Management held 616 shares of Vertex Pharmaceuticals worth $306K as of Q2 2026.
Prescott Group Capital Management sold 253 Vertex Pharmaceuticals shares in Q2 2026, an estimated $112K.
Vertex Pharmaceuticals made up 0.03% of Prescott Group Capital Management's portfolio in Q2 2026, its #273 holding.
Prescott Group Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 11 quarters since.
Prescott Group Capital Management's Vertex Pharmaceuticals position peaked at $964K in Q3 2018.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Prescott Group Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.